1. Search Result
Search Result
Results for "

MDA-MB-157

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-158683

    Kinesin Microtubule/Tubulin Cancer
    KIF18A-IN-11 (Compound 13) is a potent KIF18A inhibitor, with IC50 values of less than 100 nM in OVCAR3 and MDA-MB-157 cells. KIF18A-IN-11 can be used for the research of cancer .
    KIF18A-IN-11
  • HY-162532

    Kinesin Microtubule/Tubulin Cancer
    KIF18A-IN-10 (Compound 24) is a potent KIF18A inhibitor, with an IC50 value of 23.8 nM. KIF18A-IN-10 has anticancer activity, with IC50 values of less than 100 nM in OVCAR3 and MDA-MB-157 cells .
    KIF18A-IN-10
  • HY-162531

    Kinesin Microtubule/Tubulin Cancer
    KIF18A-IN-9 (Compound 1) is a potent KIF18A inhibitor, with an IC50 value of 3.8 nM. KIF18A-IN-9 has anticancer activity, with IC50 values of less than 100 nM in OVCAR3 and MDA-MB-157 cells .
    KIF18A-IN-9
  • HY-172957

    JAK Cancer
    JNN-5 is a potent and selective JAK2 inhibitor with an IC50 of 0.41 nM. JNN-5 shows strong antiproliferative activities in the TNBC cell lines (MDA-MB-468, MDA-MB-213, HCC70, MDA-MB-157) .
    JNN-5
  • HY-146065

    FAK Apoptosis Cancer
    FAK-IN-4 (Compound 7d) is potential FAK inhibitor with anticancer activities. FAK-IN-4 induces cell apoptosis .
    FAK-IN-4
  • HY-145827

    Kinesin Microtubule/Tubulin Cancer
    KIF18A-IN-4 is a moderately potent ATP and microtubule (MT) noncompetitive KIF18A inhibitor (IC50=6.16 μM). KIF18A-IN-4 has selectivity against a large panel of mitotic kinesins and kinases, and does not show any direct effects on tubulin assembly. KIF18A-IN-4 exhibits anti-tumor activity .
    KIF18A-IN-4
  • HY-176444

    Molecular Glues CDK Cancer
    CDK2 degrader 6 (compound 6) is an orally active and potent CDK2 molecular glue degrader with a DC50 of 46.5 nM. CDK2 degrader 6 can be used in the study of breast cancer .
    CDK2 degrader 6
  • HY-149259

    FAK Cancer
    FAK-IN-9 (Compound 8f) is a potent and orally active FAK inhibitor with an IC50 of 27.44 nM. FAK-IN-9 induces triple-negative breast cancer (TNBC) cell apoptosis .
    FAK-IN-9
  • HY-159937

    Wee1 CDK Cancer
    PKMYT1-IN-7 (compound 7) is an orally active PKMYT1 inhibitor with IC50 values of 1.6 nM and 0.06 μM against of PKMYT1 and pCDK1, respectively. PKMYT1-IN-7 suppresses the phosphorylation of CDK1 at T14 and Y15. PKMYT1-IN-7 shows anticancer activity both < and < .
    PKMYT1-IN-7

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: